Martin-Escolano, Javier , Salto-Alejandre, Sonsoles , INFANTE DOMINGUEZ, CARMEN, Carretero-Ledesma, Marta , Maldonado-Lizarazo, Natalia , Camacho-Martinez, Pedro , Martin-Dominguez, Francisco , Tallon-Ruiz, Inmaculada , Ruiz-Molina, Ana , Palacios-Baena, Zaira , Perez-Palacios, Patricia , Paniagua-Garcia, Maria , Alvarez-Marin, Rocio , Merino, Laura , Cisneros, Jose Miguel , Cordero, Elisa , Pachon, Jeronimo , Perez-Simon, Jose Antonio , Sanchez-Cespedes, Javier , Aguilar-Guisado, Manuela
No
Int. J. Infect. Dis.
Article
Científica
1
1
4.3
01/09/2024
1,28526E+12
Objectives: Patients with haematologic malignancies (HM) COVID-19 have more severe disease, with increased risk of mortality. Therefore, this study aimed to evaluate the effect of SARS-CoV-2 RNAemia and the specific humoral immune responses on the clinical outcomes of patients with HM and COVID-19. Methods: Interferon-alpha/gamma alpha / gamma (IFN- alpha /IFN- gamma ) serum levels, neutralizing antibodies and RNAemia at COVID-19 diagnosis, and persistent RNAemia during the follow-up were evaluated. Results: Overall, 63 (58.9%) out of 107 patients had RNAemia, which was persistent in 26 (41.3%) patients. RNAemia at diagnosis and persistent RNAemia were associated with the need for high-flow nasal oxygen therapy during admission. Persistent RNAemia, age > 70 years, and CURB-65 score >= 2 in patients with pneumonia were associated with increased 90-day mortality ( P = 0.009, P = 0.030 and P = 0.001, respectively). The 90-day overall survival was lower ( P = 0.006) in patients with persistent RNAemia. In addition, dexamethasone administration was associated with a COVID-19 episode with persistent RNAemia. Conclusion: Our results suggest that in patients with HM, RNAemia at the time of COVID-19 diagnosis and during the follow-up can be used to stratify patients with HM according to their clinical evolution and to guide clinical decisions tailored to the specific needs of each patient.
COVID-19; SARS-CoV-2; RNAemia; Haematologic malignancies; Clinical outcome